Pancreatic Cancer Research

ResearcherOita UniversityActive in the last 2 years

Azusa Komori

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-0591-1025; OpenAlex author ID A5109320940, A5109655609. Sources: OpenAlex.

Their work

Papers
22
Trials
0
Grants
0
Labs led
0
Collaborators
26
Papers, trials and grants by year

2021: 3 papers · 2022: 2 papers · 2023: 6 papers · 2024: 4 papers · 2025: 6 papers · 2026: 1 paper

Papers 22

  1. Nanoliposomal Irinotecan With Fluorouracil and Folinic Acid in Older Versus Younger Patients With Unresectable Pancreatic Cancer: The Multicenter NAPOLEON-2 St… Co-author DOI 10.1111/ajco.70041↗
  2. Nanoliposomal irinotecan with fluorouracil and folinic acid in patients with unresectable or recurrent pancreatic cancer: a multicenter observational study (NA… Co-author DOI 10.1016/j.esmogo.2025.100150↗
  3. Real-World Analysis of the Correlation between Overall Survival and Progression-Free Survival in Advanced Pancreatic Cancer: Results of NAPOLEON-1 and 2 Studie… Co-author DOI 10.1159/000542137↗
  4. Comparison of inflammatory markers before and after nanoliposomal irinotecan and fluorouracil with folic acid in patients with pancreatic cancer: results from … Co-author DOI 10.1177/17588359251320768↗
  5. Impact of prior chemotherapy on nanoliposomal irinotecan with fluorouracil and folinic acid for unresectable pancreatic cancer: a retrospective analysis of dat… Co-author DOI 10.1177/17588359251393156↗
  6. Impact of biliary drainage for unresectable pancreatic cancer treated with nanoliposomal irinotecan with fluorouracil and folinic acid: retrospective results f… Co-author DOI 10.1186/s12885-025-14992-2↗
  7. Efficacy of third-line chemotherapy following nanoliposomal irinotecan combined with fluorouracil and folinic acid as second-line treatment for unresectable pa… Co-author DOI 10.3389/fonc.2025.1626689↗
  8. Author Correction: C-reactive protein/albumin ratio is the most significant inflammatory marker in unresectable pancreatic cancer treated with FOLFIRINOX or ge… Co-author DOI 10.1038/s41598-024-55673-7↗
  9. A multicenter retrospective observational NAPOLEON2 study of nanoliposomal irinotecan with fluorouracil and folinic acid in patients with unresectable pancreat… Co-author DOI 10.1038/s41598-024-63172-y↗
  10. Nanoliposomal irinotecan with fluorouracil and folinic acid, FOLFIRINOX, and S-1 as second-line treatment for unresectable pancreatic cancer after gemcitabine/… Co-author DOI 10.1038/s41598-024-65689-8↗
  11. Nanoliposomal irinotecan with fluorouracil and folinic acid in patients with unresectable or recurrent pancreatic cancer: A multicenter retorospective ovservat… Co-author DOI 10.21203/rs.3.rs-3985196/v1↗
  12. Scoring model with serum albumin and CA19-9 for metastatic pancreatic cancer in second-line treatment: results from the NAPOLEON study. Co-author DOI 10.1007/s10147-023-02354-6↗
  13. C-reactive protein/albumin ratio is the most significant inflammatory marker in unresectable pancreatic cancer treated with FOLFIRINOX or gemcitabine plus nab-… Co-author DOI 10.1038/s41598-023-34962-7↗
  14. Efficacy of second-line chemotherapy after treatment with gemcitabine plus nab-paclitaxel or FOLFIRINOX in patients with metastatic pancreatic cancer. Co-author DOI 10.1038/s41598-023-46924-0↗
  15. Multicenter Retrospective Analysis of Original versus Modified FOLFIRINOX in Metastatic Pancreatic Cancer: Results of the NAPOLEON Study. Co-author DOI 10.1159/000527176↗
  16. Nanoliposomal irinotecan with fluorouracil and folinic acid in patients with unresectable or recurrent pancreatic cancer: A multicenter retrospective observati… Co-author DOI 10.21203/rs.3.rs-3677172/v1↗
  17. Conversion Surgery for Unresectable Pancreatic Cancer Treated With FOLFIRINOX or Gemcitabine Plus Nab-paclitaxel. Co-author DOI 10.21873/anticanres.16335↗
  18. Gemcitabine plus nab-paclitaxel in older patients with metastatic pancreatic cancer: A post-hoc analysis of the real-world data of a multicenter study (the NAP… Co-author DOI 10.1016/j.jgo.2021.06.011↗
  19. Prognostic nomogram for patients with unresectable pancreatic cancer treated with gemcitabine plus nab-paclitaxel or FOLFIRINOX: A post-hoc analysis of a multi… Co-author DOI 10.1186/s12885-021-09139-y↗
  20. A multicenter propensity score analysis of FOLFIRINOX vs gemcitabine plus nab-paclitaxel administered to patients with metastatic pancreatic cancer: results fr… Co-author DOI 10.1007/s10147-021-01859-2↗
  21. Gemcitabine Plus Nab-Paclitaxel Versus FOLFIRINOX in Locally Advanced, Unresectable Pancreatic Cancer: A Multicenter Observational Study (NAPOLEON Study). Co-author DOI 10.1097/mpa.0000000000001859↗
  22. Gemcitabine Plus Nanoparticle Albumin-bound Paclitaxel Versus FOLFIRINOX for Recurrent Pancreatic Cancer After Resection. Co-author DOI 10.21873/anticanres.15145↗

Closest collaborators

The 25 strongest of 26 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Junichi Nakazawa · 21 shared papers, 2021–2026 · strength 2.96
  2. Kenji Mitsugi · 21 shared papers, 2021–2026 · strength 2.96
  3. Shiho Arima · 21 shared papers, 2021–2026 · strength 2.96
  4. Futa Koga · 21 shared papers, 2021–2026 · strength 2.96
  5. Taro Shibuki · 21 shared papers, 2021–2026 · strength 2.96
  6. Mototsugu Shimokawa · 21 shared papers, 2021–2026 · strength 2.96
  7. Taiga Otsuka · 21 shared papers, 2021–2026 · strength 2.96
  8. Tsuyoshi Shirakawa · 21 shared papers, 2021–2026 · strength 2.96
  9. Hiroki Taguchi · 21 shared papers, 2021–2026 · strength 2.96
  10. Masaru Fukahori · 14 shared papers, 2021–2025 · strength 1.85
  11. Yasunori Kawaguchi · 12 shared papers, 2021–2026 · strength 1.79
  12. Keisuke Miwa · 11 shared papers, 2023–2026 · strength 1.72
  13. Norio Ureshino · 13 shared papers, 2021–2025 · strength 1.68
  14. Yasushi Ide · 13 shared papers, 2021–2025 · strength 1.68
  15. Kazuo Nishikawa · 10 shared papers, 2023–2026 · strength 1.58
  16. Shuji Arita · 10 shared papers, 2023–2026 · strength 1.58
  17. Akio Ido · 7 shared papers, 2021–2026 · strength 0.93
  18. Yoshinobu Okabe · 7 shared papers, 2021–2024 · strength 0.91
  19. Tomoko Kodama · 3 shared papers, 2023–2024 · strength 0.40
  20. Tomonori Araki · 2 shared papers, 2025 · strength 0.33
  21. Eishi Baba · 2 shared papers, 2023–2024 · strength 0.30
  22. Atsuko Kakihara · 1 shared paper, 2026 · strength 0.20
  23. Akiko Todaka · 1 shared paper, 2025 · strength 0.17
  24. Tomomi Koike · 1 shared paper, 2025 · strength 0.17
  25. Tomoyuki Ushijima · 1 shared paper, 2023 · strength 0.14

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.